Skip to main content

Table 3 Summary of the biomarkers that are significantly different between neurodegenerative disorders

From: Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic

  Aβ1–42 T-tau T-tau/Aβ1–42 P-tau NFL AβX-42 AβX-42/X-40 APPα APPβ
AD vs DLB   +
++ 		+
++ 		+
++ 		   + + +
AD vs bvFTD +
++ 		+
++ 		+++ +
++ 		+ +
++ 		+
++ 		+
++ 		+
++
AD vs PNFA +   +   +
++ 		    
AD vs SD +
++ 		+
++ 		+
++ 		+
++ 		+
++ 		+
++ 		+
++ 		  
DLB vs bvFTD +
++ 		  +    +    
DLB vs PNFA   +   + +    + +
DLB vs SD +
++ 		  +   + + +   
bvFTD vs PNFA   +
++ 		+
++ 		+    + +
++ 		+
++
bvFTD vs SD          
PNFA vs SD + + +
++ 		+    +   
  1. Biomarkers with “+” distinguish between groups with p < 0.05 from the unadjusted analysis, and “++” distinguish between groups with Bonferroni corrected p < 0.003
  2. Aβ amyloid beta, AD Alzheimer’s disease, APP amyloid precursor protein, bvFTD behavioural variant frontotemporal dementia, DLB dementia with Lewy bodies, PNFA progressive non-fluent aphasia, SD Semantic dementia, NFL neurofilament light chain, P-tau phosphorylated tau, T-tau total tau
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193